ATCOR develops and markets technologies that help clinicians identify, diagnose, and treat patients with confidence.

ATCOR develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its SphygmoCor® technology allows researchers and clinicians to non-invasively measure the central arterial pressure waveform, central aortic pressures, and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company’s SphygmoCor® system, provides clinicians with better prognostic and diagnostic information to determine the need for -  and type of intervention - effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,500 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations.

An Australian-headquartered company, ATCOR's corporate, manufacturing and R&D operations are located in Sydney. The American subsidiary, ATCOR Medical Inc., is headquartered in Naperville, Illinois.